Indeed, experimental evidence indicates that BRAF-inhibitors directly reduce the proliferation and viability of cancer cells, and indirectly prevent the metastatic process by modulating the chemokine milieu in the tumor microenvironment. The gene discussed is BRAF; the disease is neoplasm.